The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - AstraZeneca
Guilherme Rabinowits
No relevant relationships to disclose
Roy B. Tishler
Honoraria - Sanofi
Douglas Adkins
No relevant relationships to disclose
Fadlo Raja Khuri
No relevant relationships to disclose
Joseph Clark
No relevant relationships to disclose
Jochen H. Lorch
No relevant relationships to disclose
Sewanti Atul Limaye
No relevant relationships to disclose
Lori J. Wirth
Honoraria - Sanofi
Anne O'Neill
No relevant relationships to disclose
Sarah Riley
No relevant relationships to disclose
Marshall R. Posner
No relevant relationships to disclose